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ABSTRACT
Because of their ability to induce local immunosuppression and to confer cancer 
cells with resistance to apoptosis, members of the galectin family are emerging as 
a new class of actionable targets in cancer. Unfortunately, we have yet to obtain a 
clear picture of the galectin signatures in cancer cells and the surrounding tumor 
microenvironment. The aim of this study was to provide the first detailed analysis of 
the galectin signature in molecular subtypes of breast cancer. Expression signatures 
of galectins were obtained at the mRNA and protein levels. A particular attention was 
paid to stromal versus epithelial staining and to subcellular compartmentalization. 
Analysis of the stromal signature showed that gal-1, -3, -9-positive stroma were 
preferentially found in triple-negative (TN) and HER2 subtypes. In cancer cells, gal-1, 
-3, -8, and -9 showed a dual expression pattern, being found either in the cytosol or 
in the cytosol and the nucleus. TN patients with gal-8-positive nuclei had significantly 
better disease-free survival (DFS), distant-disease-free survival (DDFS), and overall 
survival (OS). In contrast, high expression of nuclear gal-1 correlated with poor 
DDFS and OS. TNBC patients who were positive for both nuclear gal-1 and gal-8 had 
5-year DFS and DDFS of 100%, suggesting a dominance of the gal-8 phenotype. 
Overall, the results indicate that specific galectin expression signatures contribute to 
the phenotypic heterogeneity of aggressive subtypes of breast cancer. Our data also 
suggest that galectins have clinical utility as indicators of disease progression and 
therapeutic targets in aggressive molecular subtypes of breast cancer.
INTRODUCTION
Gene profiling studies have greatly helped at better 
classifying breast cancer into at least four generally 
recognized molecular subtypes. Clinically, these molecular 
subtypes are identified based on the immunohistochemical 
expression of the estrogen (ER) and progesterone (PR) 
receptors and of Human Epidermal Growth Factor 
Receptor 2 (HER2), a member of the epidermal growth 
factor receptor family. These molecular subtypes include 
luminal A and B, HER2-positive, and triple negative breast 
cancer (TNBC; ER-, PR-, and HER2-negative tumor) 
[1, 2]. Because they lack actionable targets, TNBC 
and HER2-positive subtypes are thus untreatable with 
hormone therapies and have a very poor prognosis. 
The heterogeneity of HER2 and TNBCs at the molecular 
and cellular levels represents, however, a formidable 
obstacle to the development of new treatment modalities 
of these aggressive subtypes [3, 4]. Such challenge is 
further complicated by the complexity of the tumor 
microenvironment (TME) which plays a critical role in 
the disease progression [5].
Carbohydrate-dependent interactions are critical in 
many physiological processes as well as in pathological 
abnormalities, most notably in cancer. Outside the 
cells, these interactions are well known to facilitate 
intercellular communications, increasing the stability of 
growth receptors via lattice formation, and modulating 
the immune response following binding to cell surface 
receptors [6]. Inside the cells, they modulate signaling 
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cascades, direct trafficking of proteins or contribute to the 
regulation of gene expression by binding to transcription 
factors or proteins involved in mRNA splicing [7]. 
In cancer, such carbohydrate-dependent interactions 
are mediated in a large part by galectins, an evolutionarily 
ancient family of soluble proteins that bind N-linked and 
O-linked beta-galactosides via a conserved Carbohydrate 
Recognition Domain (CRD). Galectins were first isolated 
from chick muscle and calf heart and lungs and have 
since been named in the order of discovery [8, 9]. The 15 
members of the family are generally classified according 
to the number and structure of their CRD. Galectins are 
therefore divided into tandem, dimeric and chimeric 
galectins. Dimeric galectins (galectins-1, -2, -5, -7, -10, 
-11, -13, -14 and -15) have two identical CRD subunits 
while tandem ones (galectins-4, -6, -8, -9 and -12) have 
two distinct CRD subunits. Galectin-3 is the only chimeric 
galectin discovered in mammals thus far. Galectins-5 
and -6 are found only in rodents.  There is compelling 
evidence, however, that prototypic galectins might have 
non-carbohydrate binding partners and functions (reviwed 
in reference 7). These CRD-independent functions 
represent a paradigm shift in our understanding of galectin 
functions.
Our knowledge on the role of galectins in cancer 
and as biomarkers of disease progression has attracted 
the interest of many, most notably because these small 
molecular weight proteins undergo significant changes in 
their pattern of expression during progression of cancer. 
Their role in cancer progression, however, is not lacking 
in subtlety [10]. While cancer progression in accelerated 
by some galectins, others clearly inhibit tumor growth 
and/or formation of metastasis. Moreover, there is 
increasing evidence that galectins function as alarmins 
[11]. In response to aggression, they are released via a 
non-classical secretion pathway in the extracellular space 
where they play a critical role in controlling the immune 
response. Such complexity in their behavior represents 
a true challenge when developing galectin inhibitors or 
use their expression pattern as predictive biomarkers. 
Moreover, while most studies have examined one galectin 
at a time, focusing largely on galectin-1 and galectin-3, 
it is now well established that normal and tumor cells 
express more than one galectins, and that multiple 
galectins could be released in the tumor microenvironment 
(TME) [12, 13]. Defining a galectin signature for specific 
subtypes is thus critical to identify new therapeutic targets 
in concert with companion diagnostics and/or molecular 
signatures to guide therapeutic decisions. In the present 
work, we have examined the expression of seven galectins 
in breast cancer tissues by immunohistochemistry and 
correlated their expression with the different molecular 
subtypes of breast cancer.
RESULTS
In silico analysis of galectin mRNA expression in 
breast cancer tissues
We first used the prognostic module of the Breast 
Cancer Gene-Expression Miner v3.1 (bc-GenExMiner) 
public database to investigate galectin expression at the 
mRNA level among breast cancer molecular subtypes. For 
each subtype, an expression map containing the percentage 
of patients with low, intermediate, and high gene 
expression for gal-1, -2, -3, -4, -7, -8, and -9 was retrieved. 
Gene expression values were being beforehand split in 
order to form three equal groups so that “high expression” 
represents the 1/3 of the patients with highest expression 
of a gene and “low expression” is the lower 1/3 of the 
patients. For example, a representative schematic diagram 
for lgals1 shows that lgals1 expression measured in 1260 
samples is at its highest in 41% of patients with basal-like 
breast and HER2 subtypes of breast cancer (Figure 1A). 
The diagrams for other members of the galectin family are 
shown in Supplementary Figure S1. Overall, we found that 
the relative expression of galectins among the different 
molecular subtype had a similar distribution, although 
the percentage of patients with the highest expression of 
lgals8, and to a lesser extent lgals3, were lower in patients 
with a basal-like subtype (Figure 1B).
We next performed an mRNA survival analysis 
for each galectin using the Breastmark RNA expression 
database and algorithm that facilitate investigation 
of prognostic markers in the context of disease-free 
survival (DFS), distant disease-free survival (DDFS) 
and overall survival (OS) [14]. An initial search was 
performed for breast cancer as a whole, independently of 
the lymph node status and across the molecular subtypes 
classified according the PAM50 molecular classifier [15]. 
Generation of Kaplan-Meier surviving plots showed no 
significant differences of DFS between groups of patients 
with high or low expression level of genes encoding 
gal-2, -3, -4, -7, -8, and -9 (Supplementary Figure S2). The 
only notable difference was seen in patients with higher 
expression of mRNA level of lgals1. These patients had 
a significantly lower (p = 0.016) DFS than patients with 
negative/low levels of lgals1, consistent with previous 
observations that galectin-1 expression correlates with a 
poor prognosis in breast cancer [16]. High expression of 
lgals1 is indeed a poor prognostic factor for both lymph 
node (LN)-positive and negative breast cancer (Table 1). 
We next focused on aggressive molecular subtypes 
for which new prognostics are needed. In the case of HER2 
molecular subtype, we found that patients with high lgals3 
gene expression had a significantly (p = 0.031) lower 
OS than patients with lower levels of lgals3 (Figure 2). 
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In contrast, high lgals2 expression was associated with a 
good DFS, although the difference fell just short of the 
traditional definition of statistical significance (0.064). 
A similar trend was observed for lgals2 and lgals9 in 
patients with triple-negative breast cancer (Figure 3). High 
expression levels of lgals2 (p = 0.031), lgals4 (p = 0.061) 
and lgals9 (p = 0.008) were all good prognostic factors for 
LN-negative patients (Table 2). Lgals9 (p = 0.004) was 
also a good prognostic factor for patients with luminal B 
subtype. Similar results were obtained using the ssp2006 
as a classifier [17] (Data not shown). Overall, these results 
indicate that expression of galectins at the mRNA level 
can be either a good or bad prognostic markers for patients 
with aggressive subtypes of breast cancer.
Galectin protein signature in normal and 
cancerous breast tissues
We next studied the expression of galectins at the 
protein level by immunohistochemistry (IHC) using tissue 
microarrays (TMAs) constructed from 213 human breast 
cancer tumor tissues representative of each molecular 
Figure 1: Gene expression map of lgals1 in PAM50 molecular subtypes of breast cancer using bc-GenExMiner 
database. (A) The map shows the percentage of patients with low, medium and high expression of lgals1 mRNA in each molecular 
subtype: Basal-like (ER-, HER-2-), HER-2E (HER-2 enriched), Luminal A (ER+, HER-2-, low proliferation) and Luminal B (ER+, 
HER-2-, high proliferation). The number of patients for each subtypes is shown. (B) The distribution for lgals1, lgals2, lgals3, lgals4, 
lgals7, lgals8, and lgals9 in each molecular subtypes.
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Table 1: High mRNA expression as a poor prognotic factor for DFS using the pam50 classifier
Gene
Across LN-pos LN-neg Lum A Lum B HER2 Basal
n P n P n P n P n P n P n P
Lgals1 2652 0.016 744 0.049 1183 0.044 823 0.410 1013 0.614 286 0.452 424 0.047
Lgasl3 2601 0.031 714 0.546 1161 0.100 811 0.663  998 0.313 275 0.031 412 0.637
Lgals7  455 0.245 173 0.163  173 0.864 153 0.038  146 0.200  66 0.965  72 0.220
Lgals8 2497 0.726 672 0.218 1105 0.613 783 0.699  950 0.604 273 0.294 407 0.794
Figure 2: Prognostic role of galectin genes in HER2 breast cancer. Kaplan-Meier estimates of overall survival in HER2 patients 
expressing low or high galectin expression. These figures were generated using BreastMark public database.
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subtypes of breast cancer defined based on ER/PR/
HER2 status and with clinical data. We first validated 
the specificity of the IHC reactivity of the commercial 
antibodies using information from the Human Protein Atlas 
[18, 19] and a review of the literature (Supplementary 
Table S1). Representative positive IHC staining of tissues 
for each selected antibody showed a complete agreement 
with the predictions (Supplementary Figure S3). Once 
validated, the antibodies were used to examine expression 
of galectins in normal breast tissues. Our results showed 
that gal-2 and gal-4 were only weakly expressed in normal 
breast tissues, with very weak cytoplasmic staining in 
luminal cells (Figure 4). Also in normal tissues, we found 
a moderate/high cytoplasmic and/or nuclear staining 
for all galectins except gal-7, which showed its typical 
cytoplasmic and nuclear staining in myoepithelial cells 
[20] (Table 3). Gal-9 staining revealed a cytoplasmic 
staining in luminal epithelial cells. Some isolated stromal 
and epithelial cells were also strongly reactive in the 
nucleus. These patterns of expression in normal breast 
tissue were, for most galectins, significantly altered in 
breast cancer tissues. High levels of galectin expression 
were observed across all molecular subtypes, except 
for gal-7, which staining was restricted to HER2 and 
Figure 3: Prognostic role of galectin genes in triple-negative breast cancer. Kaplan-Meier estimates of OS in TNBC patients 
expressing low or high galectin expression. These figures were generated using BreastMark public database.
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Table 2: High mRNA expression as a good prognotic factor for DFS using the pam50 classifier
Gene
Across LN-pos LN-neg Lum A Lum B HER2 Basal
n P n P n P n P n P n P n P
Lgals2 2952 0.558 719 0.998 1155 0.031 807 0.795  987 0.732 275 0.064 419 0.085
Lgals4 2652 0.281 744 0.537 1183 0.061 823 0.449 1013 0.353 286 0.685 424 0.253
Lgals9 2652 0.350 744 0.393 1183 0.008 823 0.562 1013 0.004 286 0.679 424 0.083
Figure 4: Galectins expression in normal mammary gland and breast cancer tissues. Left panels, representative images 
of galectin expression in normal mammary and breast cancer tissues. The histograms on the right represent the percentage of molecular 
subtypes expressing high levels for each galectin: TN (triple-negative; ER-, PR-, HER-2-), H2 (HER-2 positive; ER-, PR-, HER-2+), 
LA (Luminal A; ER+, HER-2-), LB (Luminal B; ER+, HER-2+). LG (low grade). All scale bars 25 μm.
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triple-negative breast cancer (TNBCs). Gal-1-positive 
staining was also preferentially expressed in TNBCs 
subtype whereas expression of gal-2, -3, -4, -8, and -9 
showed an almost equal distribution in all subtypes, 
although we could not find any gal-9 positive luminal 
B samples (Table 4). High levels of gal-1 also showed 
a significant correlation with Ki-67-positive (p = 0.048) 
staining. Generation of Kaplan-Meier surviving plots 
showed that high expression levels of gal-3 (p = 0.0548) 
and gal-7 (p = 0.0786) were associated with a worse DFS 
across the molecular subtypes although the differences 
barely missed the commonly acceptable statistical 
significance of p = 0.05 (Figure 5). In the case of gal-
3, however, this difference was statistically significant 
(n = 68, p = 0.0327) for TNBC (data not shown). 
Moreover, high expression levels of gal-3 in TNBC 
patients correlated (p < 0.05) with recurrence 
(Supplementary Table S2).
Cellular localization of galectins in breast cancer 
cells 
Because previous studies have shown that galectin 
functions depends on its subcellular localization [21, 22], 
we examined the subcellular distribution of galectins 
in breast cancer cells and its association with tumor 
progression. We found that gal-1, -3, -8, and -9 have a dual 
expression patterns in breast cancer cells. Their expression 
is either restricted to the cytoplasmic compartments 
or found in the cytoplasm and the nucleus in the same 
cell (Figure 6). We found no evidence of nuclear 
localization of gal-2 and gal-4, in contrast to gal-7, which 
is almost always found in both nuclear and cytoplasmic 
compartments in the same cell (Figure 4). 
Prognostic values of subcellular galectins
In the case of gal-1 and gal-2, their respective 
nuclear and membrane localization correlated with 
TNBCs (Table 5). In contrast, gal-8 nuclear expression 
was preferentially found in low grade breast tumor 
and significantly (p < 0.0001) less frequent in TNBCs. 
Membrane-associated gal-2 (p = 0.039) also correlated 
with high expression of Ki-67. In fact, in TNBC, patients 
with gal-8-positive nuclear staining had significantly 
better DFS (p = 0.0243), DDFS (p = 0.0019), and OS 
(p = 0.0292) (Figure 7). Such correlation was also observed 
independently of the molecular subtype (Supplementary 
Figure S4). In contrast, high expression of nuclear gal-1 
correlated with a worst DDFS (p = 0.0080) and OS 
(p = 0.0294) in TNBC (Figure 8). Interestingly, patients 
who were positive for both nuclear gal-1 and nuclear gal-8 
had an actual 5-year DFS and DDFS of 100%.
Stromal galectin expression in stromal cells of 
the tumor microenvironment
There is increasing evidence that the tumor 
microenvironment is a key contributor to tumor 
progression [5]. We have thus examined whether 
galectins are expressed in stromal cells of the tumor 
microenvironment. We found that gal-1, -3, and -9 are 
commonly found in cells surrounding the tumor, while 
expression of other galectins were mostly associated 
with epithelial cancer cells (Figure 9A). In many cases, 
staining for gal-1, -3, or -9 were found in both epithelial 
and stromal cells (approximately 50% in the case of gal-1 
and gal-9 and 75% in the case of gal-3). In other cases, 
we could clearly distinguish two clear patterns of staining 
with these galectins, i.e. that gal-1, -3, and -9 expression 
were either strictly found in epithelial tissues or in stromal 
cells. Gal-1, -3, -9-positive stroma were preferentially 
found in tumours from TN and HER2 patients (Figure 9B) 
and correlated with EGFR-positive, Ki67-positive, 
and mutated p53 (Table 6). Overall, we found that 22 
patients were positive for all three galectins (Table 7). 
All were high grade tumors or were classified as TNBC/
HER2 molecular subtypes. We also found a statistically 
Table 3: Galectins distribution, cellular localization and intensity in normal mammary gland
Breast epithelial cells Stroma
Luminal cells Myoepithelial cells Intensity Localization Intensity
Gal-1 - c, n moderate e, c, n high
Gal-2 c - weak e, c moderate
Gal-3 c c high e, c, n high
Gal-4 c - weak c weak
Gal-7 - c, n moderate - -
Gal-8 c c moderate e, c moderate
Gal-9 c c, n moderate e, c, n high
Abbreviations: c, cytoplasmic; n, nuclear; e, extracellular.
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Table 4: Histoclinical correlations of breast cancers according to galectins expression in cancer cells
Gal-1 %(n) Gal-2 %(n) Gal-3 %(n) Gal-4 %(n) Gal-7 %(n) Gal-8 %(n) Gal-9 %(n)
Neg/
Low High
Neg/
Low High
Neg/
Low High
Neg/
Low High
Neg/
Low High
Neg/
Low High
Neg/
Low High
Molecular 
subtype
P = 0.001 P < 0.0001
Triple neg 14 (26) 25 (47) 6 (12) 33 (62) 9 
(16)
30 
(56)
36 (66) 4 (8) 29 (54) 10 (18) 12 (21) 29 (52) 21 (39) 18 (33)
HER-2 10 (18) 7 (13) 4 (8) 14 (26) 3 (6) 15 
(28)
15 (27) 4 (7) 13 (24) 5 (9) 3 (6) 15 (27) 10 (18) 8 (15)
Luminal 
A
26 (48) 13 (24) 11 
(21)
26 (49)
11 
(20)
27 
(50)
33 (62) 4 (7) 39 (71) 0 (0) 8 (15) 29 (52) 20 (37) 18 (33)
Luminal 
B
3 (6) 1 (2) 2 (3) 3 (5) 2 (3) 3 (5) 4 (8) 0 (0) 4 (8) 0 (0) 2 (3) 3 (5) 4 (8) 0 (0)
SBR-EE 
Grade
P = 0.006 P = 0.02 P = 0.017 P = 0.005
I (low) 14 (24) 5 (8) 8 (13) 11 (18) 1 (2) 16 (28) 15 (26) 2 (3) 18 (31) 0 (0) 5 (8) 12 (21) 11 (19) 7 (12)
III (high) 39 (67) 42 (72) 17 (29)
65 
(112)
23 
(39)
60 
(102)
74 
(127)
9 (15) 66 (113) 16 (27) 21 (36) 62 
(104)
46 (78) 36 (62)
Age, yr
≤ 45 9 (16) 11 (20) 5 (9) 15 (27) 4 (8)
15 
(27)
16 (30) 4 (7) 16 (30) 4 (7) 3 (5) 16 (29) 12 (22) 8 (15)
> 45 44 (81) 36 (66)
19 
(35)
62 
(114)
20 
(37)
61 
(111)
72 
(132)
8 (15) 69 (126) 11 (20) 22 (39)
59 
(107)
43 (79) 36 (66)
Tumor 
volume
≤ 10 cm3 31 (52) 26 (44)
14 
(23)
42 (72)
12 
(20)
44 
(75)
47 (80) 8 (14) 49 (84) 7 (12) 13 (21) 45 (75) 31 (52) 25 (43)
> 10 cm3 21 (36) 22 (37)
10 
(17)
35 (59)
14 
(24)
30 
(52)
41 (70) 4 (7) 37 (62) 7 (12) 13 (21) 30 (51) 23 (39) 21 (35)
Lymph 
node 
metastasis
Negative 32 (58) 32 (58)
13 
(23)
51 (93)
15 
(26)
49 
(87)
57 
(102)
6 (11) 56 (101) 7 (13) 15 (27) 48 (85) 35 (62) 28 (50)
Positive 20 (35) 16 (28)
11 
(19)
25 (46)
9 
(16)
28 
(50)
31 (56) 6 (11) 29 (52) 7 (13) 9 (15) 28 (49) 20 (35) 17 (31)
ER P = 0.004 P < 0.0001
Neg/Low 27 (50) 34 (62) 12 
(22)
51 (94)
12 
(22)
50 
(92)
55 
(101)
8 (15) 47 (86) 15 (27) 17 (31) 45 (82) 34 (62) 27 (50)
High 26 (48) 13 (24) 12 
(22)
26 (48)
13 
(23)
26 
(47)
34 (62) 4 (7) 39 (71) 0 (0) 8 (14) 30 (54) 22 (40) 17 (31)
PR P = 0.034 P = 0.029
Neg/ Low 43 (79) 43 (79) 20 
(38)
66 
(123)
22 
(40)
65 
(119)
76 
(141)
10 
(19)
72 (132) 15 (27) 22(40) 65 
(118)
49 (90) 37 (67)
High 10 (19) 4 (7) 3(6) 10 (19) 3 (5) 11 
(20)
12 (22) 2 (3) 14 (25) 0 (0) 3(5) 10 (18) 7 (12) 8 (14)
HER-2 
Neg/ Low 41 (74) 38 (69)
17 
(32)
60 
(110)
19 
(35)
58 
(105)
69 
(126)
8 (15) 68 (123) 10 (18) 20 (36)
57 
(102)
41 (74) 37 (66)
High 13 (24) 8 (15) 6 (11) 17 (31) 5 (9)
18 
(33)
19 (35) 4 (7) 18 (32) 5 (9) 5 (9) 18 (32) 14 (26) 8 (15)
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Figure 5: Prognostic potential of galectin in across molecular subtypes of breast cancer. Kaplan-Meier estimates of 5-year 
DFS in breast cancer patients with low or high galectin expression independently of the molecular subtype.
Ki-67 P = 0.048 P = 0.032
Neg/ Low 36 (66) 24 (44) 17 
(31)
43 (79)
14 
(25)
46 
(85)
50 (92) 9 (17) 54 (99) 6 (11) 16 (29) 43 (76) 35 (63) 25 (46)
High 18 (32) 22 (40) 7 (12) 34 (63) 11 
(20)
29 
(53)
38 (70) 3 (5) 31 (56) 9 (16) 9 (16) 32 (58) 21 (38) 19 (35)
Fisher’s exact test and chi-square test.
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significant positive correlation between expressions of 
these galectins (Figure 10).
DISCUSSION
Triple-negative breast cancer is among the most 
aggressive breast cancer subtypes. To date, there is no 
clinically available targeted therapy for patients diagnosed 
with TNBC and approximately 30% of TNBC patients 
eventually experience distant relapse. The heterogeneity 
of TNBC makes predicting treatment difficult and remains 
a major obstacle for the development of TNBC-specific 
therapeutic targets. In this study, we report that specific 
galectin expression signatures at the mRNA and protein 
levels contribute to the phenotypic heterogeneity of TNBC 
and segregate subsets of aggressive breast cancer into 
clinically meaningful subtypes. 
Gene or protein expression signatures of cancer 
tissues are generally obtained from whole tumor 
homogenates, thus reflecting the expression from all 
cell types present in the tumor. Given the critical role 
stromal cells in cancer progression, several groups have 
thus looked at defining signatures that reflects expression 
profiles of for both cancer and stromal cells [23]. Such 
strategy has shown, for instance, that the molecular 
signature of an immune response is an important 
Figure 6: Subcellular localization of galectins in breast cancer tissues. Representative IHC stainings of galectin expression in 
breast cancer tissues. All scale bars, 25 μm. The lower circle graphs show the percentage of galectin-positive staining in the cytosol only 
(C), at the membrane (M) and in the cytosol and nuclei (C/N).
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prognostic marker in breast cancer and in other cancer 
forms [23, 24]. Overall, we found that breast cancer stroma 
was rarely positive for gal-2, -4, -7, and 8. In contrast, 
gal-1, -3, and -9-positive stroma were frequent, most 
notably in aggressive molecular subtypes. Interestingly, 
when released in the extracellular space, these galectins 
have been shown to contribute induce immune tolerance 
in various physiological and pathological processes. Such 
a role as alarmins for galectins has been well documented 
in pre-eclempsia for several members for the galectin 
family, including gal-1, -3, and -9 which have been shown 
to be up-regulated preeclamptic placentas [11, 25–28]. 
Galectins are also well known for key role in modulating 
local and systemic anti-tumor responses in cancer [29]. 
This has been particularly well described for gal-1, 
induces apoptosis of IFN-γ–producing cells and skews the 
tumor microenvironment toward a Th2 cytokine profile 
[30–33]. Gal-1 also contributes to the infiltration of 
Table 5: Histoclinical correlations of breast cancers according to galectins localization in cancer 
cells
Characteristics Gal-1 % (n) Gal-2 % (n) Gal-3 % (n) Gal-8 % (n) Gal-9 % (n)
C C/N C M C C/N C C/N C C/N
Age, yr
 ≤ 45 14 (12) 9 (8) 9 (13) 10 (14) 3 (4) 17 (23) 10 (14) 11 (15) 5 (4) 14 (11)
 > 45 41 (35) 36 (31) 31 (43) 50 (71) 11 (15) 69 (96) 27 (37) 52 (70) 27 (22) 54 (44)
Tumor volume P = 0.002
 ≤ 10 cm3 33 (27) 21 (17) 24 (32) 31 (40) 8 (10) 51 (65) 16 (20) 44 (55) 14 (11) 41 (32)
 > 10 cm3 24 (19) 22 (18) 14 (19) 31(40) 7 (9) 34 (43) 22 (28) 18 (23) 17 (13) 28 (22)
Lymph node metastasis P = 0.043
 Negative 37 (32) 30 (26) 25 (34) 42 (59) 6 (8) 58 (79) 22 (29) 42 (56) 21 (17) 41 (33)
 Positive 18 (15) 15 (13) 16 (22) 17 (24) 8 (11) 28 (39) 16 (22) 20 (27) 11 (9) 27 (22)
SBR-EE Grade P < 0.0001 P = 0.024
 I (low) 6 (5) 4 (3) 12 (15) 2 (3) 1 (1) 21 (27) 2 (3) 15 (18) 1 (1) 15 (11)
 III (high) 46 (37) 44 (35) 28 (36) 58 (76) 14 (18) 64 (84) 35 (44) 48 (60) 30 (22) 54 (40)
Molecular subtypes P = 0.019 P < 0.0001 P < 0.0001
 Triple negative 22 (19) 33 (28) 7 (10) 37 (52) 7 (10) 33 (46) 24 (33) 14 (19) 17 (14) 23 (19)
 HER-2 positive 9 (8) 6 (5) 11 (15) 8 (11) 4 (5) 16 (23) 6 (8) 14 (19) 6 (5) 12 (10)
 Luminal A 22 (19) 6 (5) 20 (29) 14 (20) 3 (4) 33 (46) 7 (10) 31 (42) 9 (7) 32 (26)
 Luminal B 1 (1) 1 (1) 2 (3) 1 (2) 0 (0) 4 (5) 0 (0) 4 (5) 0 (0) 0 (0)
ER expression P = 0.007 P = 0.007 P = 0.0003
 Neg/ Low 33 (28) 40 (34) 21 (30) 45 (64) 11 (15) 55 (77) 30 (41) 30 (41) 23 (19) 38 (31)
 High 22 (19) 6 (5) 19 (27) 15 (21) 3 (4) 31 (43) 7 (10) 33 (44) 9 (7) 30 (24)
PR expression P = 0.042
 Neg/ Low 50 (43) 42 (36) 32 (45) 55 (78) 12 (17) 73 (102) 35 (47) 52 (71) 28 (23) 54 (44)
 High 5 (4) 3 (3) 8 (12) 5 (7) 1 (2) 13 (18) 3 (4) 10 (14) 4 (3) 14 (11)
HER-2 expression P = 0.023
 Neg/ Low 43 (36) 39 (33) 27 (38) 51 (72) 10 (14) 66 (91) 31 (42) 45 (60) 26 (21) 56 (45)
 High 11 (9) 7 (6) 13 (18) 9 (13) 4 (5) 20 (28) 6 (8) 18 (24) 6 (5) 12 (10)
EGFR expression P = 0.008 P = 0.044
 Neg/ Low 49 (42) 28 (24) 35 (49) 46 (65) 12 (16) 66 (90) 26 (35) 54 (72) 26 (21) 53 (42)
 High 6 (5) 17 (14) 6 (8) 13 (19) 2 (3) 20 (28) 11 (15) 9 (12) 6 (5) 15 (12)
Ki-67 expression P = 0.039 P = 0.002
 Neg/ Low 33 (28) 19 (16) 27 (38) 29 (41) 8 (11) 54 (74) 15 (20) 42 (56) 16 (13) 41 (33)
 High 21 (18) 26 (22) 13 (19) 31 (44) 6 (8) 33 (45) 23 (31) 20 (27) 16 (13) 27 (22)
Fisher’s exact test and chi-square test.
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IL-10-producing Treg1 cells to promote the tumor evasion 
[34]. In fact, we found that in some patients (n = 22), all 
three galectins are expressed in the stroma. Such triple-
positive signature was exclusively found in high grade 
BC and in TNBC (77%) or HER2 (23%) molecular 
subtypes. Not surprisingly, 75% (16/22) were expressing 
high levels of Ki-67-positive cells. These results suggest 
that stromal expression of gal-1, -3, -9 is associated with 
the most aggressive forms of breast cancer. This possibly 
explains why absence of gal-3 in preclinical mouse models 
of breast cancer does not alter tumor progression [35]. 
Future analyses with a higher number of patients will be 
needed to determine whether TNBC/HER2 patients that 
do express all three galectins in their stroma have a worst 
prognosis as patients than patients who do not express 
any or less than three of these galectins. It will also be 
interesting to identify stromal cells that express galectins 
and whether they do contribute to the presence of galectins 
in the extracellular space. Although our IHC staining does 
not allow to determine which galectins are released in the 
extracellular space and which cells are responsible for 
this secretion, historically, the presence of extracellular 
galectins has been attributed to cancer cells. We cannot 
exclude the possibility, however, that normal and/or 
Figure 7: Prognostic potential of nuclear galectin-8 in TNBC. Kaplan-Meier estimates of 5-year DFS, DDFS, and OS in TNBC 
breast cancer patients expressing cytosolic (C) or cytosolic and nuclear (C/N) galectin-8.
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cancer-associated stromal cells release soluble galectins. 
The presence of circulating levels of galectins in normal 
individuals certainly support sthis possibility. However, 
given the increasing evidence that intracellular galectins 
have many cellular functions and the strong cytosolic 
and nuclear staining that we observed in both cancer 
and stromal cells, we need to pay a particular attention 
to their role inside the cells. The emerging evidence that 
galectins have critical CRD-independent and intracellular 
functions certainly calls for a refocusing of our efforts on 
the development of new galectin-specific antagonists.
It is now well established that it is important to 
distinguish between stromal and tumor cell signatures 
to help in defining the heterogeneity of TNBCs and to 
identify new predictive tools and therapeutic targets. 
In our study, we have pushed this reasoning one step 
further by examining the subcellular compartmentalization 
of a galectins. Our approach was motivated by previous 
reports showing that members of the galectin family are 
well known for their heterogeneous pattern of expression 
and their wide range of biological functions, most notably 
as modulator of the immune response [29]. Overall, 
we found that galectins can be potential biomarkers of 
good and bad prognosis. Gal-1, -3, and -9 expressions 
in stroma or in tumor cells were all associated with a 
bad prognosis. Expression of gal-7 was also associated 
with a bad prognosis, as we previously reported [20]. 
In contrast to gal-1, -3, and -9, gal-7-positive staining was 
strictly found in the cytosol and nucleus of epithelial cells 
of approximately 25% of TNBC and HER2 molecular 
subtypes. It was not found in luminal A or B subtypes. 
In the case of gal-2, positive staining was found in all 
molecular subtypes but its membrane-associated form 
was also associated with a bad prognosis, as shown by its 
preferential association with TNBCs and Ki-67-positive 
staining. Gal-8 was the only galectin that we found was 
associated with a good prognosis. This association was 
observed when we took into consideration its nuclear 
localization in epithelial cells, which correlated with 
negative/low Ki-67 staining. Overall, these signatures are 
clearly different from that recently reported in the case 
of prostate cancer [36]. The authors found that gal-1 was 
the most abundantly expressed galectin in prostate cancer 
tissue. In contrast, other galectins (including gal-3, -4, -9, 
and 12) were expressed at lower levels whereas expression 
of gal-8 remained unchanged. Although the authors have 
not examined whether changes in subcellular localization 
or in the stromal cells occurred, these differences suggest 
that galectin signatures in cancer are tissue-specific and 
contributes to the heterogeneity of cancer (Figure 11). 
Our results showing that nuclear gal-8 is associated 
with a good prognosis and that nuclear gal-1 is associated 
with a negative prognosis are eloquent examples of 
the importance of taking into account the subcellular 
localization of proteins with a wide range of subcellular 
localization. Interestingly, in patients that expressed both 
Figure 8: Prognostic potential of nuclear galectin-1 and -8. Upper histograms, Kaplan-Meier estimates of 5-year DDFS and 
OS in TNBC breast cancer patients expressing cytosolic (C) or cytosolic and nuclear (C/N) galectin-1. Lower histograms, Kaplan-Meier 
estimates of 5-year DDFS and DFS in breast cancer patients expressing nuclear galectin-1 and/or galectin-8.
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nuclear gal-1 and gal-8, the phenotype of gal-8 was clearly 
dominant. Despite having nuclear gal-1, the 5-year survival 
rate of patients expressing nuclear gal-8 was 100%. Such 
dominance for gal-8 also suggests that both galectins have 
distinct (and contradictory) nuclear functions and that 
nuclear galectins undergo profound changes during cancer 
progression. These results uncover the clinical significance 
of nuclear gal-8 suspected from previous observations in 
normal and breast tissues [37]. Historically, gal-8 has been 
mostly recognized “matricellular extracellular protein” 
that mediates cell-matrix adhesion following binding 
to cell-surface integrins [38]. Although our approach 
is not sensitive enough to confirm the presence of gal-8 
outside the cell surface, our data showing strong nuclear 
and cytosolic gal-8 is consistent with other reports that 
have shown that gal-8 shuttles between the nucleus and 
the cytosol in cancer cells [39]. Although the molecular 
mechanism regulating gal-8 (and gal-1) trafficking in the 
nucleus is currently unknown, it will be interesting to test 
whether karyopherins are involved. These proteins have 
Figure 9: Stromal expression of galectins. (A) Representative IHC staining of galectin-1, -3, and -9 expression in epithelial (E) and 
stromal (S) cells in breast cancer tissues. All scale bars, 50 μm. (B) Bar histograms showing the percentage of cases with high levels of 
expression of stromal galectin-1, -3, and 9 in molecular subtypes. (C) Correlation between galectin-1, -3, and -9 expression in breast cancer 
tissues measured across the molecular subtypes.
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been shown to regulate nucleus-cytoplasm transport of 
galectin-3 [40]. Gal-8, however, is possibly not the only 
members of the galectin family to be associated with a 
good prognosis in breast cancer. Preliminary in silico 
analysis using the bc-GenExMiner database shows that 
high expression of lgals12, lgals13, and lgals14 correlates 
with a good prognosis in LN-negative and luminal B 
patients (Supplementary Figure S5). Future work will be 
needed, however, to determine their expression patterns 
and the good prognostic potential at the protein level. 
Table 6: Histoclinical correlations of breast cancers according to galectins expression in 
cancer-associated stroma
Characteristics
Gal-1 % (n) Gal-3 % (n) Gal-9 % (n)
Neg/Low High Neg/Low High Neg/Low High
Age, yr
 ≤ 45 16 (30) 3 (6) 15 (28) 4 (7) 15 (27) 6 (10)
 > 45 57 (104) 24 (43) 61 (112) 20 (36) 54 (98) 26 (47)
Tumor volume
 ≤ 10 cm3 43 (72) 14 (24) 42 (71) 14 (24) 39 (66) 17 (29)
 > 10 cm3 29 (49) 14 (24) 35 (59) 10 (17) 29 (49) 15 (25)
Lymph node metastasis
 Negative 48 (85) 17 (31) 48 (85) 16 (28) 42 (74) 21 (38)
 Positive 25 (45) 10 (18) 29 (51) 8 (15) 26 (47) 11 (19)
SBR-EE Grade P < 0.0001 P = 0.003 P < 0.0001
 I (low) 19 (32) 0 (0) 17 (29) 1 (1) 18 (30) 1 (1)
 III (high) 54 (92) 28 (47) 60 (102) 23 (39) 51 (87) 31 (53)
Molecular subtypes P = 0.0001 P = 0.0516 P < 0.0001
 Triple negative 23 (43) 16 (30) 26 (48) 13 (24) 19 (35) 20 (37)
 HER-2 positive 11 (20) 6 (11) 14 (26) 4 (8) 11 (21) 7 (12)
 Luminal A 35 (64) 4 (8) 33 (60) 5 (10) 34 (63) 4 (7)
 Luminal B 4 (8) 0 (0) 4 (7) 1 (1) 4 (7) 1 (1)
ER expression P < 0.0001 P = 0.031 P < 0.0001
 Neg/ Low 38 (70) 23 (42) 44 (81) 18 (33) 34 (63) 27(49)
 High 35 (65) 4 (7) 33 (60) 5 (10) 34 (63) 4 (8)
PR expression P = 0.017 P = 0.0005
 Neg/ Low 60 (111) 26 (47) 65 (119) 22 (40) 55 (101) 31 (56)
 High 13 (24) 1 (2) 12 (22) 2 (3) 14 (25) 1 (1)
HER-2 expression
 Neg/ Low 58 (105) 21 (38) 58 (106) 19 (34) 53 (96) 24 (44)
 High 15 (28) 6 (11) 18 (33) 5 (9) 16 (28) 7 (13)
EGFR expression P = 0.016 P = 0.007 P < 0.0001
 Neg/ Low 63 (114) 19 (34) 65 (119) 15 (28) 61 (110) 19 (35)
 High 10 (18) 8 (15) 11 (20) 8 (15) 7 (13) 12 (22)
Ki-67 expression P = 0.027 P = 0.007 P = 0.001
 Neg/ Low 48 (87) 13 (23) 50 (92) 10 (18) 47 (85) 13 (24)
 High 25 (46) 14 (26) 26 (48) 14 (25) 22 (40) 18 (33)
p53 expression P = 0.024 P = 0.05 P = 0.013
 Neg/ Low 57 (103) 16 (29) 59 (107) 14 (26) 53 (96) 18 (33)
 High 17 (30) 11 (20) 18 (33) 9 (17) 16 (29) 13 (24)
Fisher’s exact test and chi-square test.
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Our study is the first study that provides a detailed 
analysis of the galectin protein signature in molecular 
subtypes of breast cancer. This signature is clearly 
different from the mRNA signatures obtained from 
in silico analyses of public databases [41]. For example, 
our analysis using the bc-GenExMiner database shows 
that gal-1, -2, -3, -4, -7, -8, and -9 were all expressed at the 
mRNA level in breast tumor tissues and had a relatively 
similar distribution among the molecular subtypes. While 
such databases clearly helps in our understanding of breast 
Table 7: Histoclinical correlations of breast cancers according to galectins expression in 
cancer-associated stroma
Characteristics
Gal-1 / Gal-3 / Gal-9 stromal expression 
PNegative
n = 104
Triple positive
n = 22
Age, yr 0.562
 ≤ 45 18% (22) 2% (3)
 > 45 65% (81) 15% (19)
Tumor volume 0.466
 ≤ 10 cm3 48% (55) 9% (10)
 > 10 cm3 34% (39) 10% (11)
Lymph node metastasis 1.000
 Negative 52% (63) 12% (14)
 Positive 30% (36) 7% (8)
SBR-EE grade 0.003
 I (low) 24% (28) 0% (0)
 III (high) 58% (67) 18% (21)
Molecular subtype < 0.0001
 Triple negative 23% (29) 13% (17)
 HER-2 positive 12% (15) 4% (5)
 Luminal A 42% (53) 0% (0)
 Luminal B (HER-2+) 5% (7) 0% (0)
ER expression < 0.0001
 Neg/ Low 41% (51) 17% (22)
 High 42% (53) 0% (0)
PR expression 0.023
 Neg/ Low 66% (83) 17% (22)
 High 17% (21) 0% (0)
HER-2 expression 1.000
 Neg/ Low 64% (80) 14% (17)
 High 18% (22) 4% (5)
EGFR expression 0.0003
 Neg/ Low 72% (89) 9% (11)
 High 10% (13) 9% (11)
Ki-67 expression 0.0005
 Neg/ Low 57% (71) 5% (6)
 High 26% (32) 13% (16)
p53 expression 0.003
 Neg/ Low 65% (81) 8% (10)
 High 18% (22) 10% (12)
Fisher’s exact test and chi-square test.
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Figure 10: Correlation between galectin-1, -3, and -9 expression in breast cancer tissues. Correlations were measured across 
the molecular subtypes.
Figure 11: Schematic diagram highlighting galectin expression patterns in breast cancer tissues.
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cancer and facilitate the identification of novel intrinsic 
subtypes, caution should be exercised when evaluating 
the prognostic or therapeutic potential of a given gene, 
especially genes encoding multifunctional proteins like 
galectins. A case in point is the relevance of measuring 
cytoplasmic versus nuclear gal-8 or gal-1 staining. This is 
a critical issue given that a considerable amount of efforts 
are underway for the development of galectins inhibitors 
for the treatment of cancer. 
MATERIALS AND METHODS
In silico analysis
The prognostic module of bc-GenExMiner v3.1 
(Breast Cancer Gene-Expression Miner v3.1) [42] was 
used to correlate survival with each member of galectin 
family. Gene expression maps represent the percentage of 
patients with low, intermediate and high gene expression 
according to molecular subtypes. Kaplan-Meier survival 
curves (disease free, distance disease free and overall 
survival) of 4738 patients were obtained from the 
algorithm BreastMark [14] and the classifier PAM50 [15]. 
Patients and tumor materials
A cohort of 213 patients diagnosed with primary 
breast cancer between 2003 and 2008 at the Centre 
Hospitalier de l’Université de Montréal (CHUM) was 
used for the study. Tumors were selected on the basis of 
the histological diagnosis according to the classification 
of the Modified Scarff-Bloom-Richardson-Elston-Ellis 
grading system (SBR-EE) [43]. The cohort consisted of 
both low-grade and high-grade ductal carcinomas and of 
carcinomas with medullary features. Estrogen receptor 
status was positive in all low-grade carcinomas. This study 
was approved by the research ethics committee (CÉR) 
of the research centre at the CHUM (study SL05.019), 
in accordance with the Tri-Council Policy Statement on 
Research with Human Subjects. Consents directly from 
patients were not required in this study as per Ethics Board 
guidelines.
Tissue microarrays and immunohistochemistry
Formalin-fixed paraffin-embedded material 
from each primary tumor sample was used to construct 
tissue microarrays with an automated arrayer design to 
construct high-density tissue micro-array blocks (ATA-27 
Beecher Instruments, Sun Prairie, WI). To that end, 
triplicate 1 mm cores from each tumor and control 
tissues were punched out and arrayed into six recipient 
blocks. For immunohistochemical analysis, three-
micrometer thick sections were prepared from each TMA. 
Immunostaining reactions for each galectin were carried 
out using the Discovery XT automated immunostainer 
(Ventana Medical Systems, Tucson, AZ). Deparaffinized 
sections were incubated in cell conditioning pH 8, 
except for anti-galectin-2 (pH 6), for antigen retrieval 
and then with primary antibodies for 1 to 3 hrs: mouse 
monoclonal anti-galectin-1 (1:50; Novocastra, Leica 
Biosystems, Newcastle Upon Tyne, United Kingdom), 
rabbit polyclonal anti-galectin-2 (1:100; Proteintech 
Group, Chicago, IL, USA), rabbit monoclonal 
anti-galectin-3 (1:1000; Abcam, Cambridge, MA, USA), 
goat polyclonal anti-galectin-4 (1:200; Santa Cruz, Santa 
Cruz, CA, USA), goat polyclonal anti-galectin-7 (1:1000; 
R&D Systems, Minneapolis, MN, USA), rabbit polyclonal 
anti-galectin-8 (1:50; Abcam) and rabbit polyclonal anti-
galectin-9 (1:100; Abcam). The slides were counterstained 
with hematoxylin and bicarbonate. Each section was 
scanned at a high resolution using the Nanozoomer 
Digital Pathology (Hamamatsu, Bridgewater, NJ). The 
validation of antibodies specificity was assessed using a 
tissue microarray of 21 different human normal tissues. 
Positive and negative controls were evaluated according 
to publications. The omission of the primary antibody 
was also used as a negative control. All antibodies were 
validated by their respective company and anti-galectin-1, 
2, 3, 4 and 7 were used in previous publications [20, 44–49].
Evaluation of immunohistochemical staining
The percentage of staining was scored from 0 to 4 
according to the percentage of positive cells displaying 
galectins expression within a sample (0 (0–9%); 1 
(10–25%); 2 (26–50%); 3 (51–75%); 4 (76–100%). The 
intensity of staining was also scored from 0 to 4, with 
a score of 0 representing no staining and a score of 4 
representing the strongest staining observed. Histological 
scores were calculated by adding both scores and a strong 
expression was defined by a score of 6 to 8. This scoring 
system is somewhat comparable to the Allred score [48, 49].
Statistical analysis
Kaplan-Meier curves and relationship between 
proteins expression were assessed using GraphPad Prism 
5.00 (GraphPad Software, San Diego, CA). For Fisher’s 
exact test, chi-square test and spearman analysis, SPSS 
Statistics (IBM Corporation, Armoncon, NY) was used. 
A P value of 0.05 or less was considered statistically 
significant.
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